ArticleFrontiers in aging neuroscience2019
Ketamine: A Neglected Therapy for Alzheimer Disease.
Article in Frontiers in aging neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Ketamine or Esketamine in Special Populations of Patients With Treatment-Resistant Depression.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Increased GABBR2 Expression on Cell Membranes Causes Increased Ca2 + Inward Flow, Associated with Cognitive Impairment in Early Alzheimer's Disease.Biochemical genetics · 2025Article
- Combinatorial targeting of NMDARs and 5-HTAlzheimer's research & therapy · 2025Article
- Exploring the Neuroprotective and Neuropsychiatric Symptom Management Potential of Ketamine in Alzheimer's Disease.Cureus · 2025Review
- Ketamine does not rescue plaque load or gap detection in the 5XFAD mouse model of Alzheimer's disease.Frontiers in aging neuroscience · 2025Article
- Article
- Article
- Pathogenesis of Depression in Alzheimer's Disease.Neurochemical research · 2024Review
- Early Astrocytic Dysfunction Is Associated with Mistuned Synapses as well as Anxiety and Depressive-Like Behavior in the AppNL-F Mouse Model of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024Article
- Ketamine exerts dual effects on the apoptosis of primary cultured hippocampal neurons from fetal rats in vitro.Metabolic brain disease · 2023Article
- A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.International journal of molecular sciences · 2023Review
- Mining on Alzheimer's diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing.BMC bioinformatics · 2022Article
- Psychedelic-inspired approaches for treating neurodegenerative disorders.Journal of neurochemistry · 2022Review
- Prospects and hot spots for mammalian target of rapamycin in the field of neuroscience from 2002 to 2021.Frontiers in integrative neuroscience · 2022Article
- NMDARs Containing NR2B Subunit Do Not Contribute to the LTP Form of Hippocampal Plasticity: In Vivo Pharmacological Evidence in Rats.International journal of molecular sciences · 2021Article
- Article
- Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review.Frontiers in behavioral neuroscience · 2021Review
- Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease.Current Alzheimer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.